Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491690 | ||
| 003 | CHVBK | ||
| 005 | 20210128100511.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150401xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0704-4 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0704-4 | ||
| 245 | 0 | 0 | |a Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) |h [Elektronische Daten] |c [Shiro Saito, Kazuto Ito, Atsunori Yorozu, Manabu Aoki, Hirofumi Koga, Takefumi Satoh, Toshio Ohashi, Naoyuki Shigematsu, Shinichiro Maruo, Takashi Kikuchi, Shinsuke Kojima, Takushi Dokiya, Masanori Fukushima, Hidetoshi Yamanaka] |
| 520 | 3 | |a Background: To evaluate the safety and efficacy of brachytherapy with permanent iodine-125 seed implantation (PI) for prostate cancer. The nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) has continued since July 2005. This manuscript presents the rationale, J-POPS study design, and the characteristics of initial participants enrolled in this study from July 2005 to June 2007. Methods: All participants were treated with PI in accordance with the American Brachytherapy Society recommendations. The primary outcome measure was biochemical progression-free survival. Progression-free survival, overall survival, cause-specific survival, longitudinal changes in health-related quality of life, disease-specific quality of life, the International Prostate Symptom Score, and the incidence of adverse events were also investigated as secondary outcome measurements. Results: Overall, 6,927 patients were enrolled by the end of 2010, that is approximately 40% of all cases treated around the country. During the first 2years, 2,354 participants were enrolled and 2,339 were actually treated with PI. The age range of participants was 45 to 89years (median 69years) and their risk classifications were 1,037 (44.3%) at low risk, 1,126 (48.1%) at intermediate risk, and 134 (5.7%) at high risk, in addition to 16 participants whose classification was unknown. Of all patients, 76.6% were treated with PI without external beam radiation therapy and 49.3% received neoadjuvant hormone therapy. Conclusions: The J-POPS, a nationwide prospective cohort study that enrolled approximately 40% of all PI cases in Japan, will provide highly reliable evidence, including outcomes and quality of life, after long-term follow-up. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Brachytherapy |2 nationallicence | |
| 690 | 7 | |a Iodine-125 |2 nationallicence | |
| 690 | 7 | |a Multi-institutional prospective cohort study |2 nationallicence | |
| 690 | 7 | |a Prostate cancer |2 nationallicence | |
| 700 | 1 | |a Saito |D Shiro |u Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka Meguro-ku, 152-8902, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ito |D Kazuto |u Department of Urology, Gunma University, Gunma, Japan |4 aut | |
| 700 | 1 | |a Yorozu |D Atsunori |u Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Aoki |D Manabu |u Department of Radiation Oncology, Jikei University School of Medicine, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Koga |D Hirofumi |u Department of Urology, Hara Sanshin Hospital, Fukuoka, Japan |4 aut | |
| 700 | 1 | |a Satoh |D Takefumi |u Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan |4 aut | |
| 700 | 1 | |a Ohashi |D Toshio |u Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Shigematsu |D Naoyuki |u Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Maruo |D Shinichiro |u Translational Research Informatics Center, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Kikuchi |D Takashi |u Translational Research Informatics Center, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Kojima |D Shinsuke |u Translational Research Informatics Center, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Dokiya |D Takushi |u Department of Radiation Oncology, Saitama Medical College, Saitama, Japan |4 aut | |
| 700 | 1 | |a Fukushima |D Masanori |u Translational Research Informatics Center, Hyogo, Japan |4 aut | |
| 700 | 1 | |a Yamanaka |D Hidetoshi |u Institutes of Preventive Medicine, Kurosawa Hospital, Gunma, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 375-385 |x 1341-9625 |q 20:2<375 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0704-4 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0704-4 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Saito |D Shiro |u Department of Urology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka Meguro-ku, 152-8902, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ito |D Kazuto |u Department of Urology, Gunma University, Gunma, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yorozu |D Atsunori |u Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Aoki |D Manabu |u Department of Radiation Oncology, Jikei University School of Medicine, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Koga |D Hirofumi |u Department of Urology, Hara Sanshin Hospital, Fukuoka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Satoh |D Takefumi |u Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ohashi |D Toshio |u Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shigematsu |D Naoyuki |u Department of Radiation Oncology, Keio University School of Medicine, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Maruo |D Shinichiro |u Translational Research Informatics Center, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kikuchi |D Takashi |u Translational Research Informatics Center, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kojima |D Shinsuke |u Translational Research Informatics Center, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Dokiya |D Takushi |u Department of Radiation Oncology, Saitama Medical College, Saitama, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fukushima |D Masanori |u Translational Research Informatics Center, Hyogo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yamanaka |D Hidetoshi |u Institutes of Preventive Medicine, Kurosawa Hospital, Gunma, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 375-385 |x 1341-9625 |q 20:2<375 |1 2015 |2 20 |o 10147 | ||